BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery & Development & Advances in Neuroscience Portfolio 

BioXcel Therapeutics, Inc. recently hosted a virtual R&D Day that discussed new applications of the artificial intelligence ecosystem to augment and accelerate its drug candidate discovery and development process for neuroscience disorders with large unmet medical need. BioXcel’s neuroscience leadership team introduced BXCL502, an emerging program to bolster the company’s novel neuroscience portfolio, and reviewed the expansion of the company’s most advanced clinical development program, BXCL501.

The following members of BioXcel’s management team were joined by Robert Berman, MD, Adjunct Professor of Psychiatry, Yale University School of Medicine, who provided a deep dive into the company’s growing neuroscience pipeline and application of artificial intelligence:

• Vimal Mehta, PhD, Founder and CEO
• Frank Yocca, PhD, Chief Scientific Officer
• Robert Risinger, MD, Senior Vice President, Clinical Development
• Michael De Vivo, PhD, Vice President, Neuroscience
• Friso Postma, PhD, Senior Director, Neuroscience and Artificial Intelligence

A live webcast and accompanying presentation will be accessible through the Investors section of the company’s website or by clicking here. A webcast replay will be archived on BioXcel’s website for at least 30 days.

BXCL501 is an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of agitation associated with neuropsychiatric disorders. BioXcel believes that BXCL501 potentially targets a causal agitation mechanism, and the company has observed anti-agitation results in multiple clinical studies across several neuropsychiatric disorders, including schizophrenia-related agitation (SERENITY I), bipolar disorder related agitation (SERENITY II) and dementia related agitation (TRANQUILITY). BXCL501 has been granted Breakthrough Therapy designation for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders and dementia. The company recently received acceptance of its New Drug Application for BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders. The safety and efficacy of BXCL501 has not been established.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel’s two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation associated with neuropsychiatric disorders, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. For more information, visit www.bioxceltherapeutics.com.